APAlessandro Porchetta

Alessandro Porchetta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Porchetta has a total of 160 co-authors. Here are the top co-authors by number of shared publications:

  • Francesco Ricci

    Department of Chemical Sciences and Technologies, University of Rome, Tor Vergata, Via della Ricerca Scientifica, Rome 00133, Italy

    14 shared publications
  • Marianna Rossetti

    Department of Chemical Science and Technologies, University of Rome, Tor Vergata , Via della Ricerca Scientifica 1, Rome 00133

    13 shared publications
  • Alessandro Bertucci

    Department of Chemistry, Life Sciences and Environmental Sustainability University of Parma Parma Italy

    11 shared publications
  • Neda Bagheri

    Department of Chemical Science and Technologies, University of Rome, Tor Vergata , Via della Ricerca Scientifica 1, Rome 00133

    8 shared publications
  • Alejandro Chamorro

    Department of Sciences and Chemical Technologies University of Rome, Tor Vergata Via della Ricerca Scientifica 1 00133 Rome Italy

    6 shared publications
  • Andrea Idili

    University of Rome Tor Vergata Department of Chemical Science and Technologies Roma 00133

    6 shared publications

Latest Publications

  • Open Access

    Electrochemical DNA‐Based Biosensors for In Vivo Quantification of a Therapeutic Protein

    by Alejandro Chamorro‐Garcia, Lisa Fetter, Nicole A. Emmons, Myriam Alfonsini, Elisa Paialunga, Bettina Glahn‐Martínez, Elena Benito‐Peña, Giovanni Valenti, Alessandro Porchetta, Tod E. Kippin, et al.

    Inter‐subject pharmacokinetic variability limits the clinical effectiveness of many “biologics”, including monoclonal antibody drugs. This issue can be addressed through therapeutic drug monitoring (TDM), in which clinicians tailor dosing to individual patients based on measured plasma drug concentrations. In practice, TDM is inconvenient because current methods for quantifying protein drugs in blood are labor‐intensive and expensive. In response, here we present an electrochemical DNA‐based biosensor that addresses this issue by enabling rapid, reagentless measurement of plasma concentrations of the antibody drug trastuzumab. The approach supports real‐time, in vivo monitoring in living animals (rats). Specifically, we have systematically compared two distinct sensing architectures, a DNA scaffold sensor and an electrochemical aptamer‐based sensor, before developing an optimized sensor in the latter class that, when challenged in undiluted whole blood, can measure over the entire clinical range of the drug. When implanted in animals, the sensor successfully tracks in vivo drug concentrations and clearly visualizes differences in drug exposure between individual rats following intravenous infusion. Given the ability to generalize EAB sensors to almost any target of interest, this work illustrates a powerful new tool to guide real‐time dosing of biologic therapeutics, enabling personalized treatments of this increasingly important class of drugs.


  • Open Access

    DNA-decorated phase-shift microdroplets enable programmable coalescence and gene transfection

    by Giulia Perilli, Angela Ditri, Alessandra Vitaliti, Yosra Toumia, Alessandro Porchetta, Gaio Paradossi, Fabio Domenici

    Hypothesis. Phase-shift perfluorocarbon microdroplets (MDs) are a promising and flexible method for challenging applications in colloid science, such as customizing chemical reactions or enhancing tumor gene delivery efficiency. To achieve these goals, we focused on stable MDs made of a decafluoropentane core and a dimethyldioctadecylammonium bromide (DDAB) lipid shell that binds DNA through electrostatic interactions to create DNA-MDs assemblies.Experimental. The MDs were obtained via ultrasound homogenization and decorated with complementary DNAs. Fluorescence, confocal microscopy, and dynamic light scattering methodologies were combined to measure the binding features driving DNA-MDs formation and their coalescing interactions. The effect of the DNA-MDs at the cell interface was evaluated by MTT viability assay and DNA transfection in tumor melanoma cells.Findings. We defined the colloidal formulation of DNA-MDs, functional for both chemical and biomedical relevant applications. First, we identified the conditions that enable DNA-MDs to rapidly and selectively coalesce via oligonucleotide hybridization at the MDs interface. Then, we used DNA-MDs to efficiently enter nucleic acids into human melanoma cells, even within a two-step transfection protocol to promote intracellular DNA strand displacement.Our results could shed new light on conducting controlled reactions in small volumes, realizing microreactors, as well as designing consensus gene transfection strategies.

  • Open Access

    Synthetic DNA Transducers Integrate DNA Repair to CRISPR Signal Transduction

    by Neda Bagheri, Alessandro Bertucci, Rosa Merlo, Alessandro Porchetta

    CRISPR-based molecular diagnostics have revolutionized nucleic acid detection, yet the integration of upstream enzyme activity into programmable CRISPR output remains largely unexplored. Here, we present a synthetic transduction platform that directly couples endogenous DNA repair activity with CRISPR-Cas12a activation. By linking base excision repair (BER) events to the structural switching of a programmable DNA transducer, we convert the activity of DNA glycosylases, such as uracil DNA glycosylase (UDG) and human 8-oxoguanine glycosylase (hOGG1), into a robust fluorescence signal via Cas12a-mediated collateral (trans-) cleavage. This one-step assay allows rapid and sensitive lysate-based detection of repair activity with high specificity. In addition, it can also be easily adapted to achieve rapid throughput screening of small molecule inhibitors. The rational modular design supports the adaptation to various glycosylase activities, establishing a general framework for transducing DNA repair activity into programmable CRISPR output. Beyond bioanalytical applications, this approach paves the way for the development of synthetic gene circuits that respond to DNA repair activity and CRISPR-based drug screening platforms.


  • Open Access

    Triplex DNA clamp regulates Cas12a activation for ssDNA and RNA sensing

    by Andrea Celeste Di Pede, Neda Bagheri, Erica Belforte, Alessio Palone, Marianna Rossetti, Alessandro Porchetta

    We present a molecular strategy that enables the programmable activation of the CRISPR–Cas12a system in response to triplex DNA formation triggered by single-stranded DNA (ssDNA) or RNA inputs. Our triplex-controlled Cas12a assay leverages the high specificity of clamp-like triplex structures to control a toehold-based strand displacement reaction within a rationally designed DNA hairpin (PAM-Switch). Upon displacement and protospacer adjacent motif (PAM) complementation, the Cas12a ribonucleoprotein (RNP) is activated, initiating trans-cleavage and producing a concentration-dependent fluorescent signal. By decoupling target recognition (via triplex formation) from direct hybridization with the Cas12a–crRNA complex, the assay eliminates the need for target-specific crRNAs. This design also allows multiple detection of distinct nucleic acid (NA) targets using a single Cas12a reaction mix. Through the use of triplex-based clamps, the proposed platform achieves enhanced specificity for single-nucleotide variants and supports the detection of both ssDNA and RNA targets across a broad range of lengths (10–20 nucleotides), addressing key limitations in current Cas12a-based diagnostics and opening new avenues for NA sensing.


  • Open Access

    MARPLE: A Proximity‐Triggered CRISPR‐Cas13 Platform for Ultrasensitive Antibody Detection

    by Elena Spezzani, Luca Capelli, Denise Di Lena, Alejandro Chamorro‐Garcia, Rudy Ippodrino, Alessandro Porchetta, Alessandro Bertucci

    Monitoring clinically relevant antibodies—as biomarkers of disease or therapeutic response—is essential for informed clinical decision‐making. Traditional immunoassays like ELISA offer reliable quantification but often involve multistep workflows and limited point‐of‐care utility. New approaches coupling antibody recognition with signal amplification are therefore highly desirable. The CRISPR‐Cas13 system, known for its potent collateral cleavage activity, has emerged as a powerful diagnostic tool for nucleic acid detection. However, its application to protein biomarkers such as antibodies remains underdeveloped. Here, we introduce MARPLE (Modular Antibody Recognition via Proximity‐triggered Linker Exchange), a modular CRISPR‐Cas13–based platform for ultrasensitive antibody detection. MARPLE harnesses antibody‐induced proximity to trigger a strand displacement reaction that releases a sequestered RNA target, activating Cas13‐mediated collateral cleavage of fluorescent RNA reporters. This cascade enables detection of antibodies at femtomolar concentrations. We demonstrate MARPLE's versatility across diverse targets—including anti‐digoxigenin, anti‐cholesterol, anti‐HA, trastuzumab, and anti‐MUC1—highlighting applications in infectious disease monitoring, cancer diagnostics, and therapeutic drug tracking. The assay is isothermal, one‐pot, and retains robust performance in complex matrices such as human serum. These features establish MARPLE as a promising tool for immunodiagnostics, extending CRISPR‐based sensing beyond nucleic acids to protein biomarker detection.


  • Open Access

    Rewiring DNA Repair Activity into CRISPR Signal Transduction via Synthetic DNA Transducers

    by Neda Bagheri, Alessandro Bertucci, Rosa Merlo, Alessandro Porchetta

    Harnessing the precision of CRISPR systems for diagnostics has transformed nucleic acid detection. However, the integration of upstream cellular signals into CRISPR-based circuits remains largely underexplored. Here, we introduce a synthetic transduction platform that directly links endogenous DNA repair activity to CRISPR-Cas12a activation. By coupling base excision repair (BER) events to a programmable DNA-based transducer, our system converts the activity of DNA glycosylases, such as uracil-DNA glycosylase (UDG) and human 8-oxoguanine glycosylase (hOGG1), into a robust fluorescence signal via Cas12a-mediated trans-cleavage. This one-step CRISPR-based assay operates directly in cell lysates, enabling rapid and sensitive readout of enzymatic activity with high specificity. Additionally, it also enables in 15 minutes the throughput screening of novel potential inhibitors with high sensitivity. The modular design allows adaptation to diverse repair enzymes, offering a generalizable strategy for transforming intracellular repair events into programmable outputs. This approach lays the foundation for activity-based molecular diagnostics, synthetic gene circuits responsive to cellular states, and new tools for monitoring DNA repair in real time and drug screening.

  • Open Access

    Triplex DNA Clamp Regulates Cas12a Activation for ssDNA and RNA Sensing

    by Andrea Celeste Di Pede, Neda Bagheri, Erica Belforte, Alessio Palone, Marianna Rossetti, Alessandro Porchetta

    We present a molecular strategy that enables the programmable activation of CRISPR-Cas12a system in response to Triplex DNA formation triggered by single stranded DNA (ssDNA) or RNA inputs. This assay, called Triplex Regulated Activation of Cas12a for ssDNA and RNA sensing (TRACR), leverages the highly specificity of clamp-like triplex structures to control a strand displacement mechanism within a rationally designed DNA hairpin (PAM-Switch). Upon displacement and PAM complementation, the Cas12a ribonucleoprotein (RNP) is activated, initiating trans-cleavage and producing a concentration-dependent fluorescent signal. By decoupling target recognition (via triplex formation) from direct hybridization with the Cas12a-crRNA complex, TRACR eliminates the need for target-specific crRNAs. This design also allows multiple, spatially resolved detection of distinct nucleic acid targets within a single Cas12a reaction. Through the use of triplex-based clamps, TRACR achieves high specificity for single-nucleotide variants and supports the detection of both ssDNA and RNA targets across a broad range of lengths (10–20 nucleotides). TRACR addresses key limitations in current Cas12-based diagnostics and opens new avenues for nucleic acid sensing.

  • Open Access

    Bright and pH-sensitive Baby Spinach aptamer with RNA triplex fusion

    by Kinuko Ueno, Kaori Tsukakoshi, Norito Takeuchi, Shintaro Inaba, Andrea Idili, Alessandro Porchetta, Francesco Ricci, Kazunori Ikebukuro

    Herein, we developed a fluorescent RNA aptamer as a pH-sensitive probe for monitoring the intercellular pH condition. We demonstrated that the designed RNA triplex structure can undergo pH-sensitive structural changes and function as a pH-nanoswitch. We then combined a previously reported fluorescent aptamer with an RNA pH-nanoswitch to facilitate it becoming pH-sensitive. Using the triplex-fused fluorescent aptamer, named Bright Baby Spinach aptamer, we successfully demonstrated that this pH probe can quickly and sensitively respond to intercellular changes in pH. Surprisingly, we found that Bright Baby Spinach aptamer showed a strong fluorescence up to 13-fold higher than that of the original aptamer in cells. A possible reason for this enhancement was that the RNA triplex structure may contribute to the appropriate folding of the aptamer to bind and stack with the fluorescent ligand 3,5-difluoro-4-hydroxybenzylidene imidazolinone. Thus, fluorescence-enhanced pH-sensitive Bright Baby Spinach aptamer has the potential for rapidly and sensitively responding to intracellular changes in pH.


  • Open Access

    Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch

    by Denise Di Lena, Edoardo Sisti, Erik Brass, Erica Belforte, Bruna Marini, Alessandro Porchetta, Laura Squarcia, Eleonora Da Pozzo, Alessandro Bertucci, Rudy Ippodrino

    Therapeutic drug monitoring (TDM) is increasingly valuable for tailoring personalized therapy, particularly in managing chronic inflammatory diseases where overtreatment can cause significant side effects. Monoclonal antibodies (mAbs), a primary therapeutic approach for these conditions, face challenges from antidrug antibodies (ADAs), which can reduce mAb bioavailability and efficacy. To address these issues, we utilized Tumor Necrosis Factor α (TNF-α) as a binding moiety in a fluorescence-based programmable nanosensor within the NanoHYBRID (NH) platform developed by Ulisse Biomed S.p.A. By directly conjugating TNF-α to DNA probes, we developed a rapid, homogeneous, affinity-based assay capable of detecting multiple mAbs targeting distinct epitopes on the same protein. This NH platform effectively detected therapeutic concentrations of clinically relevant mAbs, such as Infliximab, Adalimumab, and Golimumab, in blood serum samples in a one-step process, bypassing the need for time-intensive washing steps. Moreover, the NH sensor exhibited heightened sensitivity to the presence of ADA, which impacted drug quantification, indicating its utility for monitoring bioavailable mAb levels. Compared to ELISA, the NH platform demonstrated superior sensitivity to ADAs, suggesting its potential as a highly specific, modular solution for TDM. This modular design allows the NH platform to create multiepitope nanosensors capable of measuring bioavailable mAbs in a single step.


  • Open Access

    MAIGRET: a CRISPR-based immunoassay that employs antibody-induced cell-free transcription of CRISPR guide RNA strands

    by Francesca Miceli, Sara Bracaglia, Daniela Sorrentino, Alessandro Porchetta, Simona Ranallo, Francesco Ricci

    Here we report on the development of a CRISPR-based assay for the sensitive and specific detection of antibodies and antigens directly in complex sample matrices. The assay, called Molecular Assay based on antibody-Induced Guide-RNA Enzymatic Transcription (MAIGRET), is based on the use of a responsive synthetic DNA template that triggers the cell-free in vitro transcription of a guide RNA strand upon recognition of a specific target antibody. Such transcribed guide RNA activates the DNA collateral activity of the Cas12a enzyme, leading to the downstream cleavage of a fluorophore/quencher-labeled reporter and thus resulting in an increase in the measured fluorescence signal. We have used MAIGRET for the detection of six different antibodies with high sensitivity (detection limit in the picomolar range) and specificity (no signal in the presence of non-target antibodies). MAIGRET can also be adapted to a competitive approach for the detection of specific antigens. With MAIGRET, we significantly expand the scope and applicability of CRISPR-based sensing approaches to potentially enable the measurement of any molecular target for which an antibody is available.